Can I Take Glycine with CJC-1295?

What Is CJC-1295 Modified GRF and How Does It Work?

CJC-1295 modified GRF (also called Mod GRF 1-29) is a synthetic analogue of growth-hormone-releasing hormone (GHRH). Administered subcutaneously, it binds pituitary GHRH receptors and triggers pulsatile growth hormone (GH) secretion, which then drives hepatic IGF-1 production. It is compounded under FDA 503A pharmacy rules and is not an approved drug for clinical use outside of research contexts [1].

Mechanism of GH Stimulation

The peptide preserves the first 29 amino acids of endogenous GHRH with four substitutions that resist dipeptidyl-peptidase-IV (DPP-IV) cleavage, extending the plasma half-life from roughly 7 minutes to approximately 30 minutes [2]. A single 100 mcg subcutaneous dose in healthy volunteers produces a peak GH increase of roughly 2- to 10-fold above baseline within 15 to 30 minutes, normalizing by 2 to 3 hours.

IGF-1 and Downstream Effects

Elevated GH stimulates the liver to produce IGF-1. IGF-1 promotes skeletal muscle protein synthesis, lipolysis in adipose tissue, and collagen production in connective tissue. A 2006 study by Teichman et al. (N=65) demonstrated that CJC-1295 (with DAC, a longer-acting variant) produced dose-dependent increases in IGF-1 of 28 to 72% above baseline sustained for up to 28 days after a single injection [3].

Compounding and Regulatory Context

Because CJC-1295 is not FDA-approved, it is dispensed only through licensed 503A compounding pharmacies on a valid prescription. The FDA has flagged GH secretagogue peptides in multiple guidance documents as substances that may not be compounded under 503A when bulk ingredients are not on the approved list [1]. Patients should confirm their pharmacy's compliance status before initiating therapy.

What Is Glycine and Why Do People Take It?

Glycine is the simplest amino acid and is considered non-essential because the body can synthesize it, though endogenous production may fall short of functional needs by roughly 10 g per day according to metabolic modeling published in Amino Acids [4]. Supplemental glycine at 3 to 5 g nightly is used primarily for sleep improvement, collagen support, and as a general cytoprotective agent.

Sleep Quality Evidence

A randomized crossover trial (N=11) by Bannai et al. Published in Sleep and Biological Rhythms showed that 3 g of glycine taken 1 hour before bed reduced self-reported fatigue, improved sleep-onset latency, and shortened time to slow-wave sleep on polysomnography [5]. A follow-up RCT by the same group (N=15) replicated the sleep-quality benefit and found no next-day sedation, distinguishing glycine from pharmacologic sleep aids [6].

Collagen and Connective Tissue

Glycine comprises roughly 33% of collagen by weight and is required at every third position in the Gly-X-Y repeating tripeptide. When dietary or supplemental glycine is insufficient, collagen synthesis rates decline. A controlled stable-isotope study in the American Journal of Clinical Nutrition confirmed that exogenous glycine at 5 g acutely increases fractional collagen synthesis rates in connective tissue [7].

Glycemic Effects of Glycine

At doses of 5 to 25 g, glycine acutely stimulates glucagon-like peptide-1 (GLP-1) and insulin secretion without raising blood glucose, a property studied in the context of type 2 diabetes management [8]. This mild insulinotropic effect is relevant when combined with CJC-1295, which itself can transiently suppress insulin sensitivity through GH-mediated antagonism of insulin signaling.

Does Glycine Interact with CJC-1295?

The interaction between glycine and CJC-1295 is pharmacodynamic, not pharmacokinetic. They share no common metabolic enzymes, transporters, or binding proteins. The relevant interactions involve three overlapping physiological pathways: the GH axis, sleep architecture, and collagen synthesis.

GH Axis: Additive or Complementary?

Glycine modestly stimulates GH release on its own. An oral glycine load of 6.75 g raised mean GH concentrations by approximately 3- to 4-fold in a small study of nine subjects [9]. CJC-1295 acts on the same pituitary GHRH receptor but through a different molecular trigger, meaning the GH pulses from both sources may stack additively during the window when the peptide is active. For most patients using CJC-1295 at standard compounded doses of 100 to 300 mcg, this additive effect is unlikely to push GH or IGF-1 into a pathological range, but IGF-1 monitoring remains the standard of care.

Glycemic Considerations

GH is physiologically counter-regulatory to insulin. High or sustained GH elevation reduces peripheral glucose uptake and can raise fasting glucose over weeks of therapy. Glycine, by contrast, mildly promotes insulin secretion and may partially buffer this effect [8]. The net glycemic result of co-administration has not been studied in a dedicated trial. Patients with pre-existing insulin resistance or type 2 diabetes should track fasting glucose weekly for the first 4 to 6 weeks when starting CJC-1295, regardless of glycine use.

Sleep Architecture: Overlapping Benefit

Both agents independently shift sleep toward deeper slow-wave stages. CJC-1295 is typically dosed at night to coincide with the physiological GH surge during slow-wave sleep, and glycine is most commonly taken 30 to 60 minutes before bed for the same reason. Taking both at night is consistent with published protocols and does not introduce a timing conflict. There is no evidence that combining them causes excessive somnolence.

HealthRX Clinical Framework: Nightly CJC-1295 + Glycine Co-Administration

| Timing | Agent | Dose range | Rationale | |--------|-------|-----------|-----------| | 30 to 60 min before bed | Glycine | 3 to 5 g oral | Optimizes sleep-onset benefit per Bannai et al. [5] | | Immediately before bed | CJC-1295 Mod GRF | 100 to 300 mcg subcutaneous | Aligns GH pulse with early slow-wave sleep | | Morning (fasting) | Glucose check | Self-monitoring or lab | Detects GH-mediated insulin resistance early | | Every 3 to 6 months | IGF-1 serum level | Lab | Confirms GH stimulation stays in reference range |

Is Glycine Safe with CJC-1295? What the Evidence Says

Neither agent alone has a strong safety signal at standard doses in otherwise healthy adults, and no published case reports document adverse events specifically attributable to their combination. The evidence base for CJC-1295 in humans is thin compared to the glycine literature.

Safety Profile of CJC-1295

The highest-quality human trial for CJC-1295 (with DAC) by Teichman et al. [3] reported that the most common adverse effects were transient injection-site reactions (redness, pain) in roughly 15% of subjects and transient flushing in about 10%. No serious adverse events were recorded at doses up to 60 mcg/kg. The standard compounded Mod GRF 1-29 (without DAC) has a shorter half-life and a less sustained GH elevation, making the side-effect profile generally milder in clinical practice.

Safety Profile of Glycine

Glycine at doses up to 60 g per day has been studied in schizophrenia adjunctive therapy without significant toxicity [10]. The 3 to 5 g nightly dose used for sleep is well below any threshold associated with adverse events. The FDA classifies glycine as Generally Recognized as Safe (GRAS) as a food additive [11].

Who Should Exercise Caution

Patients with active acromegaly, a history of hormone-sensitive malignancies, or poorly controlled type 2 diabetes should consult a board-certified endocrinologist before starting CJC-1295, with or without glycine. GH excess carries a documented association with colorectal neoplasia risk, and the Endocrine Society clinical practice guidelines on acromegaly note that IGF-1 normalization is a primary treatment target precisely because of this risk [12].

Monitoring Protocol While Taking Both

Routine monitoring during CJC-1295 therapy is standard regardless of co-supplements. Glycine does not require additional lab monitoring at standard doses, but the combined GH-axis effects make the following schedule reasonable.

Lab Monitoring Schedule

At baseline (before starting CJC-1295):

• Serum IGF-1
• Fasting glucose and HbA1c
• Comprehensive metabolic panel

At 6 to 8 weeks:

• Serum IGF-1 (target: mid-normal for age and sex)
• Fasting glucose

Every 3 to 6 months on stable therapy:

• Serum IGF-1
• Fasting glucose or HbA1c if baseline was borderline

The Endocrine Society notes that an IGF-1 above the age-adjusted upper reference range is the primary biochemical indicator of GH excess and should prompt dose reduction or cessation [12].

Signs That Warrant Dose Adjustment

A fasting glucose consistently above 100 mg/dL in a patient who was previously normoglycemic may indicate GH-mediated insulin antagonism. In that scenario, reducing CJC-1295 frequency from daily to 5 days on / 2 days off (a common compounding protocol) is a reasonable first step before stopping glycine, since the amino acid is unlikely to be the primary driver of glycemic change.

Practical Dosing Guidance for Co-Administration

Standard compounded CJC-1295 Mod GRF protocols in 503A telehealth settings typically run 100 to 300 mcg subcutaneously 5 to 7 nights per week, often combined with ipamorelin (a ghrelin mimetic) to deepen the GH pulse. Glycine sits outside the peptide stack and does not require timing adjustment relative to ipamorelin either, since ipamorelin also works at the pituitary level through a separate receptor (GHSR-1a).

Dose-Separation: Is It Needed?

No dose-separation window is required between glycine and CJC-1295. The two agents do not compete for the same receptor, do not share hepatic CYP450 metabolism, and are not substrates of the same transporters. Taking glycine orally and injecting CJC-1295 within the same 30-minute pre-sleep window is consistent with current telehealth prescribing patterns and raises no pharmacokinetic concern.

What to Do If You Are Already Taking Both

Patients already combining glycine and CJC-1295 who have not experienced adverse effects do not need to stop either agent. The priority action is to confirm that IGF-1 and fasting glucose have been checked within the past 3 months. If not, scheduling those labs before the next refill is the appropriate next step.

Collagen Synthesis: A Potentially Synergistic Effect

One reason practitioners sometimes intentionally pair glycine with IGF-1-elevating peptides is the theoretical combination in collagen production. Glycine provides the substrate (the limiting amino acid) while IGF-1 (raised by CJC-1295) provides the anabolic signal that upregulates collagen gene expression in fibroblasts [13]. A 2019 randomized trial in the American Journal of Clinical Nutrition (Shaw et al., N=48) showed that 15 g of gelatin (containing approximately 3 g glycine) taken with vitamin C before exercise increased collagen synthesis markers by 17% compared to placebo [7]. CJC-1295-driven IGF-1 elevation may amplify this substrate-driven effect, though a dedicated co-administration trial has not been conducted.

What Prescribers and Patients Should Know

The American Association of Clinical Endocrinologists (AACE) position statement on GH therapy states: "Growth hormone secretagogues, including GHRH analogues, remain outside the scope of approved therapeutic indications for most adults and should be used only under careful clinical oversight with biochemical monitoring." [14] That position applies fully to compounded CJC-1295 products.

Glycine, by contrast, is a low-risk amino acid supplement with a well-characterized safety profile and multiple peer-reviewed RCTs supporting its sleep and collagen benefits. Taken together, the combination is not contraindicated, but it does require the same monitoring infrastructure that any GH-axis intervention demands.

Patients using CJC-1295 through a telehealth prescriber should ensure that IGF-1 is measured at baseline and every 3 to 6 months, and should report any new-onset joint swelling, carpal-tunnel-like symptoms (common with GH excess), or unexplained fasting hyperglycemia to their clinician promptly.